董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark J. Toland | 男 | Chief Executive Officer, President and Director | 48 | 60.15万美元 | 未持股 | 2018-04-10 |
| Jeffrey Lightcap | 男 | Chairman of the Board | 59 | 未披露 | 未持股 | 2018-04-10 |
| Louis A. Cannon | 男 | Director | 59 | 4.47万美元 | 未持股 | 2018-04-10 |
| Nathan R. Harrington | 男 | Director | 49 | 3.15万美元 | 未持股 | 2018-04-10 |
| Douglas L. Braunstein | 男 | Director | 57 | 未披露 | 未持股 | 2018-04-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark J. Toland | 男 | Chief Executive Officer, President and Director | 48 | 60.15万美元 | 未持股 | 2018-04-10 |
| David W. Long | 男 | Chief Financial Officer, Senior Vice President, Treasurer, Secretary | 47 | 53.05万美元 | 未持股 | 2018-04-10 |
董事简历
中英对照 | 中文 | 英文- Mark J. Toland
-
Mark J. Toland于2016年3月7日正式被任命为总裁和首席执行官以及董事。加入Corindus之前，Toland在Boston Scientific（一家全球医疗技术领导者，主要关注心血管疾病的解决方案）任职，最近担任的职位是企业会计&全球医疗保健解决方案高级副总裁。1997年到加入Corindus之间，Toland领导Boston Scientific的大型区域和企业小组，负责美国多个心血管业务部门的商业销售和运营，包括Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology。Toland自2015年起担任The International Society of Cardiovascular Translational Research（一家非盈利组织，创建于2007年，目标是为临床应用客户更快发现治疗技术）董事。Toland持有肯塔基路易斯维尔University of Louisville工商管理理学学士学位。
Mark J. Toland was appointed as Corindus Vascular Robotics, Inc.'s President and Chief Executive Officer and a member of the Board of Directors effective March 7 2016. On June 23 2016 Mr. Toland was elected to serve as a Class III director until such time as he stands for election at the Company's 2019 Annual Meeting of Stockholders. Mr. Toland joined Corindus from Boston Scientific, a global medical technology leader with a significant focus on cardiovascular solutions, where he most recently held the position of Senior Vice President, Corporate Accounts & Global Healthcare Solutions. From 1997 until joining Corindus, Mr. Toland led large divisional and corporate teams at Boston Scientific responsible for U.S. commercial sales and operations across multiple cardiovascular business segments, including Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology. Since 2015 Mr. Toland has served as a member of the Scientific Advisory Board of The International Society of Cardiovascular Translational Research, a non-profit organization founded in 2007 with a goal to expedite scientific discovery to clinical application patients. Mr. Toland earned a B.S. in Business Administration at University of Louisville, Louisville, Kentucky. - Mark J. Toland于2016年3月7日正式被任命为总裁和首席执行官以及董事。加入Corindus之前，Toland在Boston Scientific（一家全球医疗技术领导者，主要关注心血管疾病的解决方案）任职，最近担任的职位是企业会计&全球医疗保健解决方案高级副总裁。1997年到加入Corindus之间，Toland领导Boston Scientific的大型区域和企业小组，负责美国多个心血管业务部门的商业销售和运营，包括Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology。Toland自2015年起担任The International Society of Cardiovascular Translational Research（一家非盈利组织，创建于2007年，目标是为临床应用客户更快发现治疗技术）董事。Toland持有肯塔基路易斯维尔University of Louisville工商管理理学学士学位。
- Mark J. Toland was appointed as Corindus Vascular Robotics, Inc.'s President and Chief Executive Officer and a member of the Board of Directors effective March 7 2016. On June 23 2016 Mr. Toland was elected to serve as a Class III director until such time as he stands for election at the Company's 2019 Annual Meeting of Stockholders. Mr. Toland joined Corindus from Boston Scientific, a global medical technology leader with a significant focus on cardiovascular solutions, where he most recently held the position of Senior Vice President, Corporate Accounts & Global Healthcare Solutions. From 1997 until joining Corindus, Mr. Toland led large divisional and corporate teams at Boston Scientific responsible for U.S. commercial sales and operations across multiple cardiovascular business segments, including Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology. Since 2015 Mr. Toland has served as a member of the Scientific Advisory Board of The International Society of Cardiovascular Translational Research, a non-profit organization founded in 2007 with a goal to expedite scientific discovery to clinical application patients. Mr. Toland earned a B.S. in Business Administration at University of Louisville, Louisville, Kentucky.
- Jeffrey Lightcap
-
Jeffrey Lightcap最初于2014年8月12日被任命为董事；2015年4月30日重新被任命为董事。Lightcap从2008年3月到2014年8月12日担任Corindus, Inc.（HealthCor的候选人）董事；2012年4月12日到2014年8月12日担任董事长。Lightcap自2006年10月起担任HealthCor Partners Management, LP（一家领先的增长股权投资者，主要关注诊断、治疗、医学技术和职业领域的早期和商业阶段医疗保健公司）高级总经理。Lightcap从1997年到2006年年中担任JLL Partners（一家领先的中间市场私募股权公司）高级总经理。加入JLL Partners之前，Lightcap曾担任Merrill Lynch & Co., Inc.总经理，负责Merrill Lynch并购集团的杠杆收购事宜。加入Merrill Lynch之前，Lightcap曾担任Kidder, Peabody & Co。以及Salomon Brothers并购集团高级副总裁。Lightcap还担任下列公司董事：CareView Communications, Inc. OTCQB：CRVW（一家医疗保健技术公司）；IASIS Healthcare Corporation，（一家私营公司，在高速增长的城市和郊区市场持有和运营社区医院）； Practice Partners in HealthCare（一家私营公司，专门负责门诊手术中心的管理和运营）； Paradigm Spine, LLC， （非融合脊柱植入技术领域的领导者）；以及Heartflow， （一家专注冠状动脉疾病非入侵诊断的公司）。Lightcap于1981年获得State University of New York at Stony Brook机械工程学士学位；1985年获得the University of Chicago工商管理硕士学位。Lightcap的在私募股权市场的筹资经验以及领导技能使得他有资格担任公司董事。
Jeffrey Lightcap was initially elected as a director on August 12 2014. From March 2008 to August 12 2014 Mr. Lightcap served as a director of Corindus, Inc. as an appointee of HealthCor, and he served as Chairman from April 12 2012 to August 12 2014. On June 23 2016 Mr. Lightcap was elected to serve as a Class III director until such time as he stands for election at the Company's 2019 Annual Meeting of Stockholders. Since October 2006 Mr. Lightcap has served as a Senior Managing Director at HealthCor Partners Management, LP, a leading growth equity investor in early and near commercial stage healthcare companies in the diagnostic, therapeutic, medtech and HCIT sectors. From 1997 to mid-2006 Mr. Lightcap was a Senior Managing Director at JLL Partners, a leading middle-market private equity firm. Prior to JLL Partners, Mr. Lightcap was a Managing Director at Merrill Lynch & Co., Inc. in charge of leverage buyout coverage for Merrill Lynch's mergers and acquisitions group. Prior to joining Merrill Lynch, Mr. Lightcap was a Senior Vice President in the mergers and acquisitions group at Kidder, Peabody & Co. and briefly at Salomon Brothers. Mr. Lightcap currently serves as a director of the following companies: CareView Communications, Inc. OTCQB: CRVW, a healthcare technology company; IASIS Healthcare Corporation, a privately-held company that owns and operates community focused hospitals in growing urban and suburban markets; Practice Partners in HealthCare, a privately-held company specializing in management and operation of ambulatory surgical centers; Paradigm Spine, LLC, a leader in the field of non-fusion, spinal implant technology; Heartflow, a company focused on the non-invasive diagnosis of coronary artery disease; and KellBenx, Inc., a prenatal diagnostic technology company. Mr. Lightcap received a B.E. in Mechanical Engineering from the State University of New York at Stony Brook in 1981 and in 1985 received an M.B.A. from the University of Chicago. - Jeffrey Lightcap最初于2014年8月12日被任命为董事；2015年4月30日重新被任命为董事。Lightcap从2008年3月到2014年8月12日担任Corindus, Inc.（HealthCor的候选人）董事；2012年4月12日到2014年8月12日担任董事长。Lightcap自2006年10月起担任HealthCor Partners Management, LP（一家领先的增长股权投资者，主要关注诊断、治疗、医学技术和职业领域的早期和商业阶段医疗保健公司）高级总经理。Lightcap从1997年到2006年年中担任JLL Partners（一家领先的中间市场私募股权公司）高级总经理。加入JLL Partners之前，Lightcap曾担任Merrill Lynch & Co., Inc.总经理，负责Merrill Lynch并购集团的杠杆收购事宜。加入Merrill Lynch之前，Lightcap曾担任Kidder, Peabody & Co。以及Salomon Brothers并购集团高级副总裁。Lightcap还担任下列公司董事：CareView Communications, Inc. OTCQB：CRVW（一家医疗保健技术公司）；IASIS Healthcare Corporation，（一家私营公司，在高速增长的城市和郊区市场持有和运营社区医院）； Practice Partners in HealthCare（一家私营公司，专门负责门诊手术中心的管理和运营）； Paradigm Spine, LLC， （非融合脊柱植入技术领域的领导者）；以及Heartflow， （一家专注冠状动脉疾病非入侵诊断的公司）。Lightcap于1981年获得State University of New York at Stony Brook机械工程学士学位；1985年获得the University of Chicago工商管理硕士学位。Lightcap的在私募股权市场的筹资经验以及领导技能使得他有资格担任公司董事。
- Jeffrey Lightcap was initially elected as a director on August 12 2014. From March 2008 to August 12 2014 Mr. Lightcap served as a director of Corindus, Inc. as an appointee of HealthCor, and he served as Chairman from April 12 2012 to August 12 2014. On June 23 2016 Mr. Lightcap was elected to serve as a Class III director until such time as he stands for election at the Company's 2019 Annual Meeting of Stockholders. Since October 2006 Mr. Lightcap has served as a Senior Managing Director at HealthCor Partners Management, LP, a leading growth equity investor in early and near commercial stage healthcare companies in the diagnostic, therapeutic, medtech and HCIT sectors. From 1997 to mid-2006 Mr. Lightcap was a Senior Managing Director at JLL Partners, a leading middle-market private equity firm. Prior to JLL Partners, Mr. Lightcap was a Managing Director at Merrill Lynch & Co., Inc. in charge of leverage buyout coverage for Merrill Lynch's mergers and acquisitions group. Prior to joining Merrill Lynch, Mr. Lightcap was a Senior Vice President in the mergers and acquisitions group at Kidder, Peabody & Co. and briefly at Salomon Brothers. Mr. Lightcap currently serves as a director of the following companies: CareView Communications, Inc. OTCQB: CRVW, a healthcare technology company; IASIS Healthcare Corporation, a privately-held company that owns and operates community focused hospitals in growing urban and suburban markets; Practice Partners in HealthCare, a privately-held company specializing in management and operation of ambulatory surgical centers; Paradigm Spine, LLC, a leader in the field of non-fusion, spinal implant technology; Heartflow, a company focused on the non-invasive diagnosis of coronary artery disease; and KellBenx, Inc., a prenatal diagnostic technology company. Mr. Lightcap received a B.E. in Mechanical Engineering from the State University of New York at Stony Brook in 1981 and in 1985 received an M.B.A. from the University of Chicago.
- Louis A. Cannon
-
LouisA.Cannon最初于2017年3月6日被任命为董事，担任I类董事，直到他在公司2017年年度股东大会上当选为止。Cannon博士于2017年3月加入董事会，与公司2017年3月的私募有关。Cannon博士曾是犹大沃尔克曼（Judah Volkman）的常驻学者，获得内科、心血管疾病和介入性心脏病学的三重认证。Cannon博士自2012年3月以来一直是密歇根州心脏和血管专家的执业介入心脏病学家，McLaren Northern Michigan Heart and Vascular Institute的高级项目总监，以及密歇根州北部心脏和血管研究中心的创始人兼总裁，美国最著名的私人研究中心之一。Cannon博士于1984年毕业于俄亥俄州代顿的Wright State School of Medicine，并于1991年在辛辛那提大学（University of Cincinnati）完成介入心脏病学研究金。他是BioStar Private Equity Fund I和BioStar Ventures Fund II和III的创始人和高级董事总经理。Cannon博士曾担任《财富》500强公司的战略顾问委员会成员，包括美敦力公司、雅培公司公司和波士顿科学国际有限公司。
Louis A. Cannon was initially appointed as a director on March 6 2017 to serve as a Class I director until such time as he stands for election at the Company’s 2017 Annual Meeting of Stockholders. Dr. Cannon joined the board in March 2017 in connection with the Company’s March 2017 private placement. Dr. Cannon, a past Judah Volkman Scholar in Residence, is triple board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. Since March 2012 Dr. Cannon has been a practicing Interventional Cardiologist for the Michigan Heart and Vascular Specialists, the Senior Program Director for the McLaren Northern Michigan Heart and Vascular Institute, and the founder and President of the Cardiac & Vascular Research Center of Northern Michigan, one of the nation’s most prominent private research centers. Dr. Cannon graduated from Wright State School of Medicine in Dayton, Ohio in 1984 and completed his Interventional Cardiology fellowship at the University of Cincinnati in 1991. He is the founder and Senior Managing Director of BioStar Private Equity Fund I and BioStar Ventures Fund II and III. Dr. Cannon has served on the strategic advisory boards for Fortune 500 companies including Medtronic, Abbott Laboratories, and The Boston Scientific Corporation. - LouisA.Cannon最初于2017年3月6日被任命为董事，担任I类董事，直到他在公司2017年年度股东大会上当选为止。Cannon博士于2017年3月加入董事会，与公司2017年3月的私募有关。Cannon博士曾是犹大沃尔克曼（Judah Volkman）的常驻学者，获得内科、心血管疾病和介入性心脏病学的三重认证。Cannon博士自2012年3月以来一直是密歇根州心脏和血管专家的执业介入心脏病学家，McLaren Northern Michigan Heart and Vascular Institute的高级项目总监，以及密歇根州北部心脏和血管研究中心的创始人兼总裁，美国最著名的私人研究中心之一。Cannon博士于1984年毕业于俄亥俄州代顿的Wright State School of Medicine，并于1991年在辛辛那提大学（University of Cincinnati）完成介入心脏病学研究金。他是BioStar Private Equity Fund I和BioStar Ventures Fund II和III的创始人和高级董事总经理。Cannon博士曾担任《财富》500强公司的战略顾问委员会成员，包括美敦力公司、雅培公司公司和波士顿科学国际有限公司。
- Louis A. Cannon was initially appointed as a director on March 6 2017 to serve as a Class I director until such time as he stands for election at the Company’s 2017 Annual Meeting of Stockholders. Dr. Cannon joined the board in March 2017 in connection with the Company’s March 2017 private placement. Dr. Cannon, a past Judah Volkman Scholar in Residence, is triple board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. Since March 2012 Dr. Cannon has been a practicing Interventional Cardiologist for the Michigan Heart and Vascular Specialists, the Senior Program Director for the McLaren Northern Michigan Heart and Vascular Institute, and the founder and President of the Cardiac & Vascular Research Center of Northern Michigan, one of the nation’s most prominent private research centers. Dr. Cannon graduated from Wright State School of Medicine in Dayton, Ohio in 1984 and completed his Interventional Cardiology fellowship at the University of Cincinnati in 1991. He is the founder and Senior Managing Director of BioStar Private Equity Fund I and BioStar Ventures Fund II and III. Dr. Cannon has served on the strategic advisory boards for Fortune 500 companies including Medtronic, Abbott Laboratories, and The Boston Scientific Corporation.
- Nathan R. Harrington
-
NathanR.Harrington是公司董事的新提名人。Harrington自2011年10月起在Philips梦百合担任多个业务开发职位，并于2016年9月被任命为Philips Image Guided Therapies Business Group业务开发主管。加入Philips公司之前，他曾任职Boston Scientific公司（全球医疗技术领导者，专注于心血管解决方案）8年以上，在那里他曾担任其心脏、节律和血管集团的新业务开发职务，以及其外围干预部门的产品管理职务。在加入Boston Scientific之前，Harrington先生在管理咨询领域工作了6年多，专注于梦百合和评估新兴医疗技术的商业潜力。Harrington先生于1990年在布朗大学（Brown University）获得学士学位，并于1996年在耶鲁大学（Yale University）获得工商管理硕士学位。
Nathan R. Harrington is a new nominee for director of the Company. Since October 2011 Mr. Harrington has served in various Business Development roles at Philips Healthcare and, in September 2016 was appointed as Head of Business Development for Philips' Image Guided Therapies business group. Prior to joining Philips, Mr. Harrington worked for over 8 years at Boston Scientific, a global medical technology leader with a significant focus on cardiovascular solutions, where he held positions in New Business Development for its Cardiac, Rhythm and Vascular Group and in Product Management for its Peripheral Interventions Division. Prior to Boston Scientific Mr. Harrington spent over 6 years in Management Consulting, with a focus on healthcare and evaluating the commercial potential of emerging medical technology. Mr. Harrington earned a B.A. from Brown University in 1990 and an MBA from Yale University in 1996. - NathanR.Harrington是公司董事的新提名人。Harrington自2011年10月起在Philips梦百合担任多个业务开发职位，并于2016年9月被任命为Philips Image Guided Therapies Business Group业务开发主管。加入Philips公司之前，他曾任职Boston Scientific公司（全球医疗技术领导者，专注于心血管解决方案）8年以上，在那里他曾担任其心脏、节律和血管集团的新业务开发职务，以及其外围干预部门的产品管理职务。在加入Boston Scientific之前，Harrington先生在管理咨询领域工作了6年多，专注于梦百合和评估新兴医疗技术的商业潜力。Harrington先生于1990年在布朗大学（Brown University）获得学士学位，并于1996年在耶鲁大学（Yale University）获得工商管理硕士学位。
- Nathan R. Harrington is a new nominee for director of the Company. Since October 2011 Mr. Harrington has served in various Business Development roles at Philips Healthcare and, in September 2016 was appointed as Head of Business Development for Philips' Image Guided Therapies business group. Prior to joining Philips, Mr. Harrington worked for over 8 years at Boston Scientific, a global medical technology leader with a significant focus on cardiovascular solutions, where he held positions in New Business Development for its Cardiac, Rhythm and Vascular Group and in Product Management for its Peripheral Interventions Division. Prior to Boston Scientific Mr. Harrington spent over 6 years in Management Consulting, with a focus on healthcare and evaluating the commercial potential of emerging medical technology. Mr. Harrington earned a B.A. from Brown University in 1990 and an MBA from Yale University in 1996.
- Douglas L. Braunstein
-
Douglas L. Braunstein，2013年1月1日以来，他担任副主席。从2010年6月至2010年12月31日，他担任首席财务官。2008年以来，他担任美国投资银行业务的负责人。此后，他担任各种高级投资银行业务职务，包括全球并购负责人。
Douglas L. Braunstein was initially appointed as a Class I director on March 16 2018 in connection with the 2018 Private Placement. Mr. Braunstein is the Managing Partner and Founder of Hudson Executive Capital since 2015. Previously, Mr. Braunstein served in various roles at JP Morgan Chase & Co., including as Vice Chairman from 2013 to 2015 Chief Financial Officer and member of the company's Operating Committee from 2010 to 2012 as well as serving in a number of leadership roles in the investment bank, including as a member of the Management Committee from 2000 to 2010. Mr. Braunstein currently serves on the board of Eagle Pharmaceuticals, Inc. He is a Trustee of Cornell University. He also serves on Harvard Law School's Dean's Advisory Board. He is a member of the Economic Club of New York, a Board Member of the Foreign Policy Association, a member of the UJA of Greater New York's Wall Street and Financial Services Division, and on the Board of Directors of the Gordon A. Rich Memorial Foundation. He graduated with a B.S. from Cornell University in 1983 and a J.D. from Harvard Law School in 1986. - Douglas L. Braunstein，2013年1月1日以来，他担任副主席。从2010年6月至2010年12月31日，他担任首席财务官。2008年以来，他担任美国投资银行业务的负责人。此后，他担任各种高级投资银行业务职务，包括全球并购负责人。
- Douglas L. Braunstein was initially appointed as a Class I director on March 16 2018 in connection with the 2018 Private Placement. Mr. Braunstein is the Managing Partner and Founder of Hudson Executive Capital since 2015. Previously, Mr. Braunstein served in various roles at JP Morgan Chase & Co., including as Vice Chairman from 2013 to 2015 Chief Financial Officer and member of the company's Operating Committee from 2010 to 2012 as well as serving in a number of leadership roles in the investment bank, including as a member of the Management Committee from 2000 to 2010. Mr. Braunstein currently serves on the board of Eagle Pharmaceuticals, Inc. He is a Trustee of Cornell University. He also serves on Harvard Law School's Dean's Advisory Board. He is a member of the Economic Club of New York, a Board Member of the Foreign Policy Association, a member of the UJA of Greater New York's Wall Street and Financial Services Division, and on the Board of Directors of the Gordon A. Rich Memorial Foundation. He graduated with a B.S. from Cornell University in 1983 and a J.D. from Harvard Law School in 1986.
高管简历
中英对照 | 中文 | 英文- Mark J. Toland
Mark J. Toland于2016年3月7日正式被任命为总裁和首席执行官以及董事。加入Corindus之前，Toland在Boston Scientific（一家全球医疗技术领导者，主要关注心血管疾病的解决方案）任职，最近担任的职位是企业会计&全球医疗保健解决方案高级副总裁。1997年到加入Corindus之间，Toland领导Boston Scientific的大型区域和企业小组，负责美国多个心血管业务部门的商业销售和运营，包括Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology。Toland自2015年起担任The International Society of Cardiovascular Translational Research（一家非盈利组织，创建于2007年，目标是为临床应用客户更快发现治疗技术）董事。Toland持有肯塔基路易斯维尔University of Louisville工商管理理学学士学位。
Mark J. Toland was appointed as Corindus Vascular Robotics, Inc.'s President and Chief Executive Officer and a member of the Board of Directors effective March 7 2016. On June 23 2016 Mr. Toland was elected to serve as a Class III director until such time as he stands for election at the Company's 2019 Annual Meeting of Stockholders. Mr. Toland joined Corindus from Boston Scientific, a global medical technology leader with a significant focus on cardiovascular solutions, where he most recently held the position of Senior Vice President, Corporate Accounts & Global Healthcare Solutions. From 1997 until joining Corindus, Mr. Toland led large divisional and corporate teams at Boston Scientific responsible for U.S. commercial sales and operations across multiple cardiovascular business segments, including Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology. Since 2015 Mr. Toland has served as a member of the Scientific Advisory Board of The International Society of Cardiovascular Translational Research, a non-profit organization founded in 2007 with a goal to expedite scientific discovery to clinical application patients. Mr. Toland earned a B.S. in Business Administration at University of Louisville, Louisville, Kentucky.- Mark J. Toland于2016年3月7日正式被任命为总裁和首席执行官以及董事。加入Corindus之前，Toland在Boston Scientific（一家全球医疗技术领导者，主要关注心血管疾病的解决方案）任职，最近担任的职位是企业会计&全球医疗保健解决方案高级副总裁。1997年到加入Corindus之间，Toland领导Boston Scientific的大型区域和企业小组，负责美国多个心血管业务部门的商业销售和运营，包括Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology。Toland自2015年起担任The International Society of Cardiovascular Translational Research（一家非盈利组织，创建于2007年，目标是为临床应用客户更快发现治疗技术）董事。Toland持有肯塔基路易斯维尔University of Louisville工商管理理学学士学位。
- Mark J. Toland was appointed as Corindus Vascular Robotics, Inc.'s President and Chief Executive Officer and a member of the Board of Directors effective March 7 2016. On June 23 2016 Mr. Toland was elected to serve as a Class III director until such time as he stands for election at the Company's 2019 Annual Meeting of Stockholders. Mr. Toland joined Corindus from Boston Scientific, a global medical technology leader with a significant focus on cardiovascular solutions, where he most recently held the position of Senior Vice President, Corporate Accounts & Global Healthcare Solutions. From 1997 until joining Corindus, Mr. Toland led large divisional and corporate teams at Boston Scientific responsible for U.S. commercial sales and operations across multiple cardiovascular business segments, including Interventional Cardiology, Peripheral, Structural Heart, and Electrophysiology. Since 2015 Mr. Toland has served as a member of the Scientific Advisory Board of The International Society of Cardiovascular Translational Research, a non-profit organization founded in 2007 with a goal to expedite scientific discovery to clinical application patients. Mr. Toland earned a B.S. in Business Administration at University of Louisville, Louisville, Kentucky.
- David W. Long
David W. Long最先于2014年8月12日被任命为公司首席财务官、高级副总裁、财务主管和秘书；2015年4月30日重新被任命为相同职位。Long从2011年9月到2014年8月12日担任Corindus, Inc.首席财务官和行政副总裁；加入Corindus, Inc.之前，Long从2004年9月到2011年9月担任Thermo Fisher Scientific Corporation金融副总裁和分区总监。Long持有University of Massachusetts Lowell工商管理理学学士学位；the University of Pennsylvania政府管理硕士学位。
David W. Long was initially appointed as Corindus Vascular Robotics, Inc.'s Chief Financial Officer, Senior Vice President, Treasurer and Secretary on August 12 2014 and was re-elected and re-appointed to serve in the same capacities on April 30 2015. From September 2011 to August 12 2014 Mr. Long served as Chief Financial Officer and Vice President of Administration of Corindus, Inc. Prior to joining Corindus, Inc., Mr. Long served in positions as Vice President of Finance and Division Controller at Thermo Fisher Scientific Corporation from September 2004 to September 2011. Mr. Long earned his B.S. in Business Administration from the University of Massachusetts Lowell and his Masters in Government Administration from the University of Pennsylvania.- David W. Long最先于2014年8月12日被任命为公司首席财务官、高级副总裁、财务主管和秘书；2015年4月30日重新被任命为相同职位。Long从2011年9月到2014年8月12日担任Corindus, Inc.首席财务官和行政副总裁；加入Corindus, Inc.之前，Long从2004年9月到2011年9月担任Thermo Fisher Scientific Corporation金融副总裁和分区总监。Long持有University of Massachusetts Lowell工商管理理学学士学位；the University of Pennsylvania政府管理硕士学位。
- David W. Long was initially appointed as Corindus Vascular Robotics, Inc.'s Chief Financial Officer, Senior Vice President, Treasurer and Secretary on August 12 2014 and was re-elected and re-appointed to serve in the same capacities on April 30 2015. From September 2011 to August 12 2014 Mr. Long served as Chief Financial Officer and Vice President of Administration of Corindus, Inc. Prior to joining Corindus, Inc., Mr. Long served in positions as Vice President of Finance and Division Controller at Thermo Fisher Scientific Corporation from September 2004 to September 2011. Mr. Long earned his B.S. in Business Administration from the University of Massachusetts Lowell and his Masters in Government Administration from the University of Pennsylvania.